Benzinga | Oct 15, 2021 08:35AM EDT

Albireo To Showcase New Data At AASLD The Liver Meeting On Nov. 16

Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(r) 2021, being held virtually November 12 -- 15. Data will be presented in one oral presentation and six posters across studies in rare pediatric cholestatic liver disease and in adult liver disease. Highlights to include data from the Phase 3 PEDFIC 1 study and PEDFIC 2 long-term extension study of Albireo's product, Bylvay (odevixibat), and data from studies of viral disease product candidate, A2342. Abstracts are now available on the AASLD website and in the October supplement of HEPATOLOGY.

Pediatric Liver Presentations

Oral: Relationships Between Changes in Autotaxin, Pruritus, and Serum Bile Acids After Odevixibat Treatment in Patients With Progressive Familial Intrahepatic Cholestasis: Data From a Pooled Analysis

Presenter: Dr. Emmanuel Gonzal?s, Associate Professor of Pediatric Hepatology and Liver Transplantation, University Hospitals of Paris-Sud, Bicetre, France

Session: Pediatric Hepatology: Metabolic and Genetic Diseases

Date & Time: Saturday, November 13, 4:00 p.m. EST

Poster #1950: Effects on Serum Bile Acids, Pruritus, and Safety With Up to 72 Weeks of Odevixibat Treatment: Pooled Data From the PEDFIC 1 and PEDFIC 2 Studies in Children With Progressive Familial Intrahepatic Cholestasis

Session Title: Pediatric Hepatology: Pediatric Liver Disease - Basic Science; Biliary Atresia and Neonatal Cholestasis; Viral and Autoimmune Liver Disease; Metabolic and Genetic Diseases; Pediatric Liver Transplantation

Poster #1951: Efficacy and Safety Outcomes With Odevixibat in Children With Progressive Familial Intrahepatic Cholestasis Due to Deficiencies in Multidrug Resistance Protein 3 (PFIC Type 3) or Myosin 5B (PFIC Type 6)

Session Title: Pediatric Hepatology: Pediatric Liver Disease - Basic Science; Biliary Atresia and Neonatal Cholestasis; Viral and Autoimmune Liver Disease; Metabolic and Genetic Diseases; Pediatric Liver Transplantation

Poster #1969: Natural Variation of Serum Bile Acid Levels and Pruritus in Children With Progressive Familial Intrahepatic Cholestasis: Pretreatment Data From Patients In The Phase 3 PEDFIC 1 Study

Session Title: Pediatric Hepatology: Pediatric Liver Disease - Basic Science; Biliary Atresia and Neonatal Cholestasis; Viral and Autoimmune Liver Disease; Metabolic and Genetic Diseases; Pediatric Liver Transplantation

Poster #1957: Hepatic Parameters, Growth, and Sleep With Responders and Nonresponders to Odevixibat Treatment: Pooled Data From the PEDFIC 1 and PEDFIC 2 Studies in Children With Progressive Familial Intrahepatic Cholestasis

Session Title: Pediatric Hepatology: Pediatric Liver Disease - Basic Science; Biliary Atresia and Neonatal Cholestasis; Viral and Autoimmune Liver Disease; Metabolic and Genetic Diseases; Pediatric Liver Transplantation